Results 91 to 100 of about 3,595 (167)

Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

Global & Regional Health Technology Assessment
Introduction: The therapeutic approach to the patient with acute bacterial skin and skin structure infection (ABSSSI) and complicated infections often involves the early transition from intravenous to oral therapy (early switch) or early discharge.
Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera   +10 more
doaj   +1 more source

Dalbavancin Dosage

Clinical Infectious Diseases, 2018
Selma, Tobudic, Florian, Thalhammer
openaire   +2 more sources

Dalbavancin: a novel antimicrobial.

International journal of clinical practice, 2007
The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens.
Chen, A Y, Zervos, M J, Vazquez, J A
openaire   +2 more sources

P-1892. Dabbling with Dalbavancin: Implementation and Cost-savings of an Inpatient-to-Outpatient Dalbavancin Pathway

Open Forum Infectious Diseases
Background Dalbavancin is a lipoglycopeptide antibiotic with in vitro activity against gram-positive organisms and a terminal half-life of 14.4 days. One dose provides 7 days of therapy whereas a novel 2-dose regimen provides up to 4-6 weeks.
Melissa O’Neal, N. Piccicacco, K. Zeitler, J. Weber, D. Mcconnell, Chris Conn, Kari Carrieri, S. Hall, Jose Montero   +8 more
semanticscholar   +1 more source

Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

Journal of Global Antimicrobial Resistance
Objectives: To retrospectively describe the patterns of use of dalbavancin for treating infections in diabetic patients in Italian and Spanish standard clinical practice.
Laura Morata Ruiz, Alessandro Ruggieri, Marco Falcone, Juan Pasquau Liaño, Ivan Gentile, Miguel Salavert Lletí, Leonor Moreno Núñez, Antonio Cascio, Carlo Tascini, Maria Loeches Yagüe, Francesco Giuseppe De Rosa, Alessandra Ori, Alessandro Comandini, Agnese Cattaneo, Paolo Antonio Grossi   +14 more
doaj   +1 more source

Leukocytoclastic Vasculitis Induced by Dalbavancin: A Case Report. [PDF]

Am J Case Rep
Scaglione V, Cola M, Sasset L, Fortarezza F, Casarin C, Trevenzoli M, Dei Tos AP, Cattelan A.   +7 more
europepmc   +1 more source

Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. [PDF]

Open Forum Infect Dis
Stohs EJ, Alexander BT, Fey PD, Foreman MCL, Xu L, Penewit K, Waalkes A, Salipante SJ, Werth BJ.   +8 more
europepmc   +1 more source

Case Series: Use of Dalbavancin for Invasive Gram-Positive Infection in Children. [PDF]

J Pediatr Pharmacol Ther
Chang AJ, Mannix MK, Kenney PO, Vermilye KN, Rebello GLA, Zwiener J, Hines AG, Sato A, Islam SM, Gómez-Duarte OG, Yu KOA.   +10 more
europepmc   +1 more source

Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children. [PDF]

BMC Res Notes
Ajapuje PS, Sameel S, Gaikwad D, Kumar PS, Dharangutti R.   +4 more
europepmc   +1 more source

Dalbavancin [PDF]

, 2020
openaire   +1 more source